mAbxience news

HK inno.N said it has signed an exclusive license agreement with Spain’s mAbxience to market the latter’s Prolia (ingredient: denosumab) biosimilar, a preventive treatment for osteoporosis and cancer-related skeletal complications, in Korea.

Under the contract, HK inno.N will exclusively market two types of denosumab biosimilars – 60 mg and 120 mg — from mAbxience, and will apply for domestic approval and proceed with sales.

Denosumab is an antibody tre

To drive scientific exchange on biopharmaceuticals and high-quality treatment options, more than 180 physicians, pharmacists, and hospital managers from around the world came together in a global conference and over 423 attendees via streaming. On October 21, mAbxience, a leading international biopharmaceutical company of which Fresenius Kabi acquired a majority stake, has celebrated its 2nd Biosimilar Forum at Madrid. In a live-streamed event, experts in the field discussed current topics su

• A further milestone for Fresenius Kabi’s Vision 2026 growth strategy as the company invests on the core growth vector “Broaden in Biopharma”
• The combination of both companies positions Fresenius Kabi for accelerated medium- and long-term growth building on a highly complementary product offering in one of the fastest-growing areas of healthcare
• Enables entry into high-growth biologics Contract Development and Manufacturing (“CDMO”) mark

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Biologics License Application (BLA) for bevacizumab-maly, a biosimilar referencing Avastin^®. The product will be marketed under the proprietary name ALYMSYS^® and represents the third bevacizumab biosimilar approved in the U.S.

ALYMSYS^®

• This agreement will bring new business to the biotech company, which is expanding its manufacturing capabilities and maintains its identity, brand, and complete team
• The transaction validates mAbxience differentiated core competencies in the development, manufacturing and commercialization of biopharmaceutical products
• With this strategic transaction the Spanish group Insud will also have resources to increase its current growth investments’ worldwide
</